Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program

09 Jan 2018

• By Sue Sutter

Pink Sheet Perspectives 2017 - 2018

Related Content

Patient-Focused Guidance Writing: FDA Aiming For 'Sweet Spot' In Advice

22 Dec 2017

FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

12 Sep 2017

FDA Ends Regularly Scheduled Patient-Focused Drug Development Meetings

29 Sep 2017

Patient Experience Data May Require Separate Label, Genentech Suggests

26 Sep 2017

FDA's 21<sup>st</sup> Century Cures Plan Gives Patient-Focused Drug Development A Boost

10 Jul 2017

Will Patient-Reported Data Require New Drug Labeling Framework?

06 May 2017

Case Studies: How Patient Input Is Changing R&D

09 Jan 2018

'Patient Experience Data' Section Added To US FDA Drug Reviews

09 Jan 2018

Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

10 Jun 2015

Related Companies

Genentech, Inc.

Additional Topics

United States Clinical Trials Drug Review FDA Policy BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.